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Summary The expression of pS2 was examined histochemically in paraffin sections taken from biopsy
material from patients diagnosed with ductal carcincoma in situ (DCIS). Often intense immunoreactivity, to an
anti-pS2 monoclonal antibody, was observed in comedo, solid, cribriform and micropapillary types of DCIS,
with significant positivity found in 63-67% of cases. In 15 samples analysed, we found a good correlation
between pS2 expression and presence of progesterone receptor positive cells, but not with estrogen receptor. There was only a limited degree of correspondence between the cells staining with these anti-sera. Some pS2
positive cells were also seen in normal acini in areas adjacent to cancer but much less frequently in sections of
normal breast from reduction mammoplasty. Most normal areas were negative, as were cysts. In benign
proliferative conditions (seen in sections with and without DCIS) such as adenosis, sclerosing adenosis, mild
and florid ductal epithelial hyperplasia, significant pS2 positivity was seen in about 50% of cases.
These results suggest that there is a progressive increase in pS2 from normal to benign to cancer cells and
that this gene is expressed in both the invasive and pre-invasive forms of breast cancer.
The pS2 gene, which was originally isolated by virtue of its
estrogen-inducibility (Masiakowski et al., 1982), has been
shown to be predominantly associated with estrogen receptor
(ER) positive breast cancers (Rio et al., 1987; Skilton et al.,
1989; Henry et al., 1989). Limited pS2 immunostaining has
also been reported in normal breast and in parts of the ileum
(Piggott et al., 1991; Luqmani et al., 1992), as well as more
extensive expression in the stomach, but is otherwise absent
from the vast majority of normal tissues. It is however,
widely expressed in other epithelial cancers (Henry et al.,
1991; Luqmani et al., 1989; Rio et al., 1988; Luqmani et al.,
1991; Wysocki et al., 1990) as well as in inflammatory condi-
tions of the gastro-intestinal tract (Rio et al., 1991; Seitz et
al., 1992). pS2 has significant sequence homology with the
(pancreatic) spasmolytic polypeptide (hSP) Wright et al.,
1990) with which it is co-expressed in gastric mucosa (Theis-
inger et al., 1991) and is also secreted into the gastric fluid
(Rio et al., 1988).
In a small study we have recently (Shousha et al., manu-
script submitted) found pS2 to have no prognostic
significance in patients with colo-rectal cancer, but high pS2
levels were predictive of both longer survival (Foekens et al.,
1990) and favourable response of breast cancer patients to
endocrine therapy (Henry et al., 1989; Skilton et al., 1989)
and, in this regard, may be superior to ER (Schwartz et al.,
1991). Little is known of the expression ofpS2 in early breast
cancer. We therefore carried out an immunohistochemical
study using archival material obtained from patients who had
been diagnosed with ductal carcinoma in situ (DCIS), a
neoplastic condition in which the malignant cells are confined
within the basement membranes of the mammary ducts. This
is believed to constitute a fore-runner of the invasive type of
carcinoma which involves penetration through the basement
membrane into the surrounding stromal tissue.
Materials and methods
Tissues
Archival paraffin embedded material was used for this study.
The tissue blocks containing biopsies taken from patients
diagnosed with DCIS, were either from the Histopathology
department at Charing Cross Hospital or kindly made
available by Mr J.C. Gazet from St George's Hospital. Each
case of DCIS was further classified as comedo, solid, cribri-
form or micropapillary type using widely accepted histo-
logical criteria (Page et al., 1987). The blocks containing
formalin fixed normal breast tissue from reduction mammo-
plasty specimens were kindly provided by Dr J. Gomm.
Immunohistochemistry
pS2 Paraffin sections (5ym) cut into polylysine coated
slides were de-waxed and re-hydrated in phosphate buffered
saline (PBS) pH 7.4 after rinsing in alcohol. Endogenous
peroxidase was blocked by incubation (5 min at 20°C) in
methanol containing 3% hydrogen peroxide. Following a
brief rinse in PBS (5min), sections were incubated with
non-immune sheep serum (2.5% in PBS containing 0.5%
BSA) to block non-specific Fc receptors. After rinsing in
PBS, sections were incubated overnight at 4°C with mouse
anti-pS2 monoclonal antibody (diluted 1:150). After washing
with more PBS (3 x 5 min), the sections were incubated with
biotinylated horse anti-mouse immunoglobulin (1:1000 dilu-
tion) (this and subsequent reactions utilised a Vectastain kit)
for 30 min. This was washed off by rinsing twice in PBS for
5 min each. The streptavidin-peroxidase complex was added
and after 45 min removed by rinsing in PBS (3 x 5 min).
Visualisation was achieved by a final incubation in
diaminobenzidine (Sigma, UK). After rinsing in tap water,
sections were counterstained with Harris haematoxylin. Con-
trols were run in parallel, in which the pS2 antibody was
replaced with non-immune serum. The relative degree of
staining was assessed as before (Luqmani et al., 1989) and
scored from negative (-) to highly positive ( + + + ). This
method of analysis was preferred to ones which involve
estimation of the percentage of cells stained in a number of
microscope fields.
Estrogen andprogesterone receptor
For ER staining (Elias et al., 1990), 5 tcm paraffin sections
were kept at 37'C overnight prior to dewaxing. Endogenous
peroxidase was blocked by incubation in 3% hydrogen
peroxide in methanol. After rinsing with PBS at 37°C, sec-
tions were incubated with pronase (Sigma, UK) for 9 min at
37°C followed by washing in ice cold PBS for 3 min and
storage at - 20°C for Omin. After another rinse with PBS
at 20'C, blocking reagent (ERICA kit from Abbott
Laboratories Ltd UK) was added for 30 min followed by an
overnight incubation at 20'C with two drops of the ER
Correspondence: Y.A. Luqmani.
Received 27 May 1992; and in revised form 14 October 1992.
Br. J. Cancer (1993), 67, 749-753 '." Macmillan Press Ltd., 1993750 Y.A. LUQMANI et al.
monoclonal antibody. After rinsing in PBS, an additional
two drops of ER antibody were added and left for 2 h at
38°C before another PBS rinse and incubation with biotiny-
lated rabbit anti-rat IgG (Vector Laboratories, UK) (1:100
dilution in PBS) for 1 h at 20°C. After washing in PBS,
sections were incubated with 0.05% diaminobenzidine
(Sigma, UK) and 0.01% hydrogen peroxide containing
0.05% imidazole in Tris-HCI pH 7.2 for 10 min. Sections
were then washed in PBS followed by running tap water,
briefly immersed in 1% osmium tetroxide, washed in tap
water and counterstained with haematoxylin.
For PR (Soomro & Shousha, 1990), paraffin sections
prepared as for ER, were covered with normal goat serum
for 30 min, then incubated with two drops of PR monoclonal
antibody (Abbott Laboratories, UK) at 4°C overnight. After
rinsing in 0.2 M Tris buffered saline, sections were incubated
with biotinylated anti-rat IgG (1:100 dilution) for 2 h, then
rinsed and incubated with avidin-biotin complex (Dako) for
2 h, followed by procedures described for ER, before
counterstaining.
In both cases nuclear staining was assessed semi-
quantitatively as either negative or positive (weak and
strong).
Results
DCIS
We obtained biopsies from 47 patients originally diagnosed
as having DCIS. However, in the sections which we
examined, histological evidence of DCIS was seen in only 35
of these. In most cases, there was more than one type of
DCIS present on the section, except in the case of the
papillary variant, which appeared exclusively, in 9/12 cases.
In all but one instance, the occurrence and degree of pS2
positivity was similar for each type when found together. The
frequency of significant positivity ( + / + + / + + + ) was the
same for all four types, ranging from about 63-67% of cases
in which they were observed. There was no consistent
difference in the pattern of staining, although in the comedo
type, the immunoreactivity was usually associated with the
cells on the periphery away from the necrotic center whilst in
the other types, it was more uniformly distributed. Figure 1
shows an example of the staining in each type. The staining
was generally more intense than we have previously observed
with invasive carcinomas. A single case with lobular
carinoma in situ was weakly positive.
Table I pS2 expression in cases with DCIS
pS2 positivity
DCIS type No. - + + + + + + +
Comedo 21 6(2) 1 6(2) 2 6
Solid 19 3(1) 4 3 3 6
Cribriform 11 4(1) 1 1 1 4
Micropapillary 12 2(1) 2(2) 5(4) 1(1) 2(1)
Figures in brackets indicate No of cases with one type only in the
section: rest contained more than one type.
Table II pS2 expression in non-malignant histological conditions
Histological pS2 positivity
feature No.a - + + + +
Normal elements 33 17 12 3 1
Cysts 17 13 3 1
Adenosis 8 2 2 4
Schlerosing adenosis 4 1 1 2
Mild hyperplasia 3 1 2
Florid ductal 5 2 1 1 1
hyperplasia
aRefers to number of sections in which the particular feature was
observed.
Figure 1 Immunoperoxidase staining of formalin fixed sections showing reactivity with pS2 monoclonal antibody in a, solid b,
comedo c, cribriform and d, micropapillary DCIS variants. Scale bars represent 70tLM for a and 170JiM for b-d.pS2 IN INTRA-DUCT BREAST CANCER 751
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Correlation ofpS2 with ER and PR
In order to determine whether pS2 was present in exactly the
same cells as PR and whether it was restricted to those that
were also ER positive, we examined 12 cases containing
DCIS that were pS2 positive and three that were negative,
for the presence of ER and PR, by staining parallel sections.
We found that 10/12 of the pS2 positive samples had PR
positive cells but only 5/12 had ER positive staining. All
three of the pS2 negative samples were PR negative. There
was some degree of correspondence between the cells staining
with the pS2 and PR anti-sera, but this was not always the
case; sometimes different tumour cells in the same section
stained with only one or other of the anti-sera. Thus
although there was a good overall correlation between pS2
and PR, this did not necessarily reflect co-expression within
the same cells. Figure 2 shows parallel sections containing a
focus of solid DCIS in which the cells did express both pS2
and PR, but were negative for ER.
Non-malignant elements
In many samples (both those containing DCIS and those in
which no cancer cells were observed) we also found normal
as well as other non-malignant elements. The staining pattern
observed with these is summarised in Table II. Normal
lobules were found in 33 of the 46 cases and significant pS2
staining was seen in four of these, although some positivity
was also seen in 12 other cases, predominantly as an intense
reaction in a few scattered acini. The majority of cases with
adenosis, sclerosing adenosis and either mild or florid ductal
epithelial hyperplasia, had weak (mostly ± / + compared to
DCIS) immunostaining in those areas. An example of one of
these is shown in Figure 3a: panel b shows a rare case of
staining in cells within a lobule of normal appearance whilst
panel c shows a similar lobule in which most of the normal
acini are negative, but a few cells, which appear to have
atypical nuclei, as positive. In contrast, positive staining in
cysts was seen in only 4/17 cases in which they were found.
Although the number of cases examined was relatively small,
we observed no obvious difference in the staining of the
hyperplastic conditions whether or not the section also had
elements of DCIS.
Reduction mammoplasty specimens
For comparison, we stained sections of specimens obtained
from breast reduction surgery, which apart from one case of
virginal hyperplasia, had cytologically normal ducts and
lobules. In three cases there was no staining at all while in
the other three, including the case mentioned above, a few
epithelial cells showed weak (±) reactivity.
Discussion
In this study we have shown that pS2, hitherto examined
predominantly in invasive breast cancers (Rio et al., 1987;
Henry et al., 1989; Skilton et al., 1989), is sporadically ex-
pressed in apparently normal epithelia, especially in areas
adjacent to cancer, but much less so in normal breast alveoli
found in reduction mammoplasty specimens where there are
no malignant cells. Piggott et al.; (Piggott et al., 1991) also
observed positive staining in normal breast but in a much
higher proportion of samples, while Rio et al.; (Rio et al.,
1987) reported no staining of normal cells at the periphery of
cancers. However, in specifically looking for this difference,
we have found that there is a progressive increase in
immunoreactivity, from normal to benign hyperplastic
I
Figure 3 pS2 immunostaining of areas of non-malignant breast within sections containing DCIS. a, shows reactivity in cells within
an apparently normal breast lobule and b, in an area of sclerosing adenosis. c, shows an example of a normal breast lobule in
which one acini has abnormal looking cells which are strongly positive. Scale bar represents 400jM in a and b and 40ylM in c.752 Y.A. LUQMANI et al.
lesions, to neoplastic cells, including those that have not yet
become invasive. As seen in Figure 3c, whereas most normal
cells are pS2 negative, immunoreactivity is associated with
the appearance of cells displaying abnormal characteristics.
Cysts, which may be likened to dilated acini with little
other signs of abnormality, were a commonly observed
feature and only a few expressed pS2 protein. Sclerosing
adenosis, a relatively common benign lesion of the mammary
lobule, whose presence is thought to be associated with an
increased risk for developing breast carcinoma (Jensen et al.,
1989) and in which DCIS has been reported to develop
occasionally (Eusebi et al., 1989) was in contrast,
predominantly pS2 positive. Thus it is still unclear whether
the pS2 protein has any real physiological role in the normal
breast; it's appearance there may simply reflect beginnings of
abnormalities restricted to sporadic cells. Increased incidence
of pS2 expression in epithelial hyperplasia is interesting in
view of recent opinions regarding this as one of the most
critical potential precursors of breast cancer with an in-
creased risk of 4-7 fold (Bulbrook & Miller, 1980).
The detection of DCIS, regarded as an obligate precursor
of invasive cancer (Carter & Eggleston, 1977), appears to be
increasing, presumably as a direct result of more widespread
mammographic screening. This presents an opportunity for
identifying genetic changes involved in tumour invasion.
DCIS shows a marked expression of pS2, characterised by
often intense focal staining which, in our past experience with
this antibody, is not a general feature of invasive cancers in
which the staining is less intense and more heterogeneous
(Luqmani et al., 1992). A similar finding has been reported
for c-erbB-2 staining of comedo carcinomas where these have
been seen with invasive elements (Maguire et al., 1991). Our
results would suggest that pS2 is already highly expressed in
malignant cells before they have acquired the propensity for
invasion, as indeed is c-erbB-2 (Maguire et al., 1991). How-
ever, unlike the latter (Bartkova et al., 1990), we found pS2
to be present in both the comedo and non-comedo types.
Interestingly, the frequency of ER staining ofparaffin embed-
ded DCIS cases has been reported (Giri et al., 1989) to be
much greater in cribriform, papillary and solid types
(>50%) as compared with comedo (<20%). This discord-
ance between pS2 and ER staining, also reflected by our own
ER results, suggests that pS2 expression may not be
obligatorily linked to that of ER as originally envisaged (Rio
et al., 1987). Even the close correlation of pS2 with PR was
due as often as not, to an assessment of the overall staining
on parallel sections, than to co-expression in the same cells.
Although the comedo type of DCIS appears to have a
histologically more aggressive phenotype and seems to be
associated with a greater risk of advancement to invasive
cancer, there is considerable uncertainty regarding diagnostic
criteria for these lesions and a lack of reliable prognostic
markers to predict which tumours are likely to become
invasive. As mastectomy has until recently been the standard
treatment, information on disease recurrence is sparse, but
several small studies (Campbell et al., 1992; Fuqua et al.,
1991) have indicated subsequent development of invasive
cancer only in a minority of patients with DCIS. The urgent
need for prognostic markers, to provide less radical breast
conserving treatment, is self evident and is likely to become a
much debated issue (Fentiman, 1990) as the number of
screen detected early cancers rise. In view of our initial
observations we consider that it would be of value to
examine pS2 expression in a larger series where follow-up
data is available.
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